Finding new uses for existing drugs to treat a rare bleeding disorder.
Repurposing drugs to treat Hereditary Hemorrhagic Telangiectasia: identification using a vascularized HHT on-a-chip microphysiological system platform
This study is looking for new ways to help people with Hereditary Hemorrhagic Telangiectasia (HHT) by testing existing medications to see if they can be used to treat the condition and improve blood vessel health.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-11038808 on NIH RePORTER |
What this research studies
This research focuses on Hereditary Hemorrhagic Telangiectasia (HHT), a rare condition that causes abnormal blood vessel formations leading to severe bleeding episodes. Using a specialized microphysiological system, researchers will screen a library of existing drugs to identify potential treatments that can be repurposed for HHT patients. The study aims to understand the genetic causes of HHT and how these affect blood vessel behavior, ultimately seeking to improve treatment options for those affected by this debilitating disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Hereditary Hemorrhagic Telangiectasia, particularly those experiencing frequent bleeding episodes.
Not a fit: Patients with other bleeding disorders or those not diagnosed with HHT may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for patients suffering from HHT, reducing their bleeding episodes and improving their quality of life.
How similar studies have performed: While research on repurposing drugs for rare diseases is ongoing, this specific approach using a microphysiological system for HHT is relatively novel.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Hughes, Christopher C. W. — University of California-Irvine
- Study coordinator: Hughes, Christopher C. W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.